Sionna Therapeutics (NASDAQ:SION) Trading Down 4.2% – Here’s Why

Sionna Therapeutics, Inc. (NASDAQ:SION)’s stock price was down 4.2% during trading on Monday . The stock traded as low as $13.11 and last traded at $13.11. Approximately 40,547 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 232,004 shares. The stock had previously closed at $13.69.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Stifel Nicolaus began coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a “buy” rating and a $32.00 price objective on the stock. TD Cowen began coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They set a “buy” rating for the company. Finally, Guggenheim began coverage on shares of Sionna Therapeutics in a report on Tuesday, March 4th. They issued a “buy” rating and a $45.00 target price on the stock.

Sionna Therapeutics Stock Up 6.9 %

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Thursday, March 20th. The company reported ($3.38) earnings per share for the quarter, missing the consensus estimate of ($2.68) by ($0.70).

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.